CARsgen Therapeutics Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in discovering, researching, and developing cell therapies. The firm focuses on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company was founded by Zong Hai Li and Hua Mao Wang on February 9, 2018, and is headquartered in Shanghai, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company